Oncoclínicas do Brasil Serviços Médicos S.A (ONCO3) Fair Value & Analysis
Healthcare · BR · Market cap R$954M
Fair value as of: Jul 17, 2026
From 3 valuation models · updated 24 days ago
Share price −41.5% over the past month.
Below-average quality, and screening another 23% overvalued on our models.
What matters now
- Weak quality (20/100) and above fair value at the same time, the margin of safety is missing on both counts.
- A fairly wide model range (R$0.2600 to R$0.6700) leaves room in how you read the outcome.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range R$0.5500 – R$19.24 · fair‑value band R$0.2600 – R$0.6700 · the R$0.6200 price screens above the R$0.4800 fair value. Dashed = 300-day average. As of Jul 17, 2026.
Analysis
Oncoclínicas do Brasil Serviços Médicos S.A (ONCO3) currently trades at R$0.6200, while our model-based Fair Value estimate is R$0.4800, implying the stock looks roughly 22.6% overvalued today. The Quality Score stands at 20/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).
Over the trailing twelve months, Oncoclínicas do Brasil Serviços Médicos S.A generated revenue of R$5.4B at a net margin of -71.1%. Revenue declined 22.3% year over year. Net debt stands at R$3.3B. Fundamentals as of Jul 17, 2026
Our scenario range runs from R$0.2600 (bear case) to R$0.6700 (bull case); at R$0.6200, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -23%, ONCO3 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 3 models by family
Widest divergence: Asset-Based (R$0.5400) versus Dividend Discount (R$0.4200). Highest evidence: Gordon GGM (70).
Notify me when ONCO3 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 21 · Market factors (momentum, volatility) 10
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America.
Full company description
Oncoclínicas do Brasil Serviços Médicos S.A., together with its subsidiaries, provides oncology, hematology, radiotherapy, and genomics healthcare services in Latin America. The company offers treatment services, including radiotherapy, hormone therapy, immunotherapy, port-a-cath, palliative care, target therapy, breast cancer hormone therapy, bone marrow transplant, non-oncological infusions, chemotherapy, oral chemotherapy, and prostate cancer hormone therapy; and surgery procedures, such as breast, head and neck, lung, prostate cancer, stomach, bladder cancer, oncological, kidney cancer, gynecological, and testicular cancer. It also provides diagnostics services comprising pathological analysis, genetic testing, molecular journey, personalized medicine and individualized treatment, myelogram-bone marrow biopsy, and ONCO test-PDO. In addition, the company offers treatment support services, which include veinviewer, cryotherapy, integrative medicine, and DeLife, as well as hilotherapy, laser therapy, OC care line, OC precision medicine, OncoACCESS, survivorship, and telemedicine services. Oncoclínicas do Brasil Serviços Médicos S.A. was founded in 2010 and is headquartered in São Paulo, Brazil.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Oncoclínicas do Brasil Serviços Médicos S.A reported revenue of R$5.7B in FY2025 versus R$2.7B in FY2021, a compound +20.7%/yr. Reported net income was −R$3.6B in FY2025.
ONCO3 screens 23% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Oncoclínicas do Brasil Serviços Médicos S.A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Oncoclínicas do Brasil Serviços Médicos S.A (ONCO3) overvalued or undervalued?
What is the fair value of ONCO3?
What is the quality score of ONCO3?
What is the revenue of Oncoclínicas do Brasil Serviços Médicos S.A (ONCO3)?
What is the net profit margin of ONCO3?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Oncoclínicas do Brasil Serviços Médicos S.A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.